Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Is Reaction Time Slowing an Early Sign of Alzheimer's Disease? A Meta-Analysis.

Andriuta D, Diouf M, Roussel M, Godefroy O.

Dement Geriatr Cogn Disord. 2019 Aug 13:1-8. doi: 10.1159/000500348. [Epub ahead of print]

PMID:
31408867
2.

Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer's Disease Before 51 Years.

Lacour M, Quenez O, Rovelet-Lecrux A, Salomon B, Rousseau S, Richard AC, Quillard-Muraine M, Pasquier F, Rollin-Sillaire A, Martinaud O, Zarea A, de la Sayette V, Boutoleau-Bretonniere C, Etcharry-Bouyx F, Chauviré V, Sarazin M, le Ber I, Epelbaum S, Jonveaux T, Rouaud O, Ceccaldi M, Godefroy O, Formaglio M, Croisile B, Auriacombe S, Magnin E, Sauvée M, Marelli C, Gabelle A, Pariente J, Paquet C, Boland A, Deleuze JF, Campion D, Hannequin D, Nicolas G, Wallon D; collaborators of the CNR-MAJ.

J Alzheimers Dis. 2019;71(1):227-243. doi: 10.3233/JAD-190193.

PMID:
31381512
3.

Systematic Review and Meta-Analysis of Prevalence in Post-Stroke Neurocognitive Disorders in Hospital-Based Studies.

Barbay M, Diouf M, Roussel M, Godefroy O; GRECOGVASC study group.

Dement Geriatr Cogn Disord. 2018;46(5-6):322-334. doi: 10.1159/000492920. Epub 2018 Nov 30.

4.

Is VLSM a valid tool for determining the functional anatomy of the brain? Usefulness of additional Bayesian network analysis.

Arnoux A, Toba MN, Duering M, Diouf M, Daouk J, Constans JM, Puy L, Barbay M, Godefroy O.

Neuropsychologia. 2018 Dec;121:69-78. doi: 10.1016/j.neuropsychologia.2018.10.003. Epub 2018 Oct 25.

PMID:
30449718
5.

Dysexecutive disorders and their diagnosis: A position paper.

Godefroy O, Martinaud O, Narme P, Joseph PA, Mosca C, Lhommée E, Meulemans T, Czernecki V, Bertola C, Labauge P, Verny M, Bellmann A, Azouvi P, Bindschaedler C, Bretault E, Boutoleau-Bretonniere C, Robert P, Lenoir H, Krier M, Roussel M; GREFEX study group.

Cortex. 2018 Dec;109:322-335. doi: 10.1016/j.cortex.2018.09.026. Epub 2018 Oct 17. Review.

PMID:
30415091
6.

Neuroimaging Determinants of Poststroke Cognitive Performance.

Puy L, Barbay M, Roussel M, Canaple S, Lamy C, Arnoux A, Leclercq C, Mas JL, Tasseel-Ponche S, Constans JM, Godefroy O; GRECogVASC Study Group.

Stroke. 2018 Nov;49(11):2666-2673. doi: 10.1161/STROKEAHA.118.021981.

PMID:
30355190
7.

Who should undergo a comprehensive cognitive assessment after a stroke? A cognitive risk score.

Godefroy O, Yaïche H, Taillia H, Bompaire F, Nédélec-Ciceri C, Bonnin C, Varvat J, Vincent-Grangette F, Diouf M, Mas JL, Canaple S, Lamy C, Arnoux A, Leclercq C, Tasseel-Ponche S, Roussel M, Barbay M; GRECogVASC Study Group.

Neurology. 2018 Nov 20;91(21):e1979-e1987. doi: 10.1212/WNL.0000000000006544. Epub 2018 Oct 17.

PMID:
30333160
8.

Structural, Microstructural, and Metabolic Alterations in Primary Progressive Aphasia Variants.

Routier A, Habert MO, Bertrand A, Kas A, Sundqvist M, Mertz J, David PM, Bertin H, Belliard S, Pasquier F, Bennys K, Martinaud O, Etcharry-Bouyx F, Moreaud O, Godefroy O, Pariente J, Puel M, Couratier P, Boutoleau-Bretonnière C, Laurent B, Migliaccio R, Dubois B, Colliot O, Teichmann M.

Front Neurol. 2018 Sep 18;9:766. doi: 10.3389/fneur.2018.00766. eCollection 2018.

9.

Acute Dementia After Deep Brain Stimulation in Parkinson Disease.

Puy L, Tir M, Lefranc M, Yaïche H, Godefroy O, Krystkowiak P.

World Neurosurg. 2018 Nov;119:63-65. doi: 10.1016/j.wneu.2018.07.197. Epub 2018 Jul 31.

PMID:
30075264
10.

Cognitive Impairments and Dysexecutive Behavioral Disorders in Chronic Kidney Disease.

Puy L, Bugnicourt JM, Liabeuf S, Desjardins L, Roussel M, Diouf M, Chillon JM, Choukroun G, Massy ZA, Godefroy O.

J Neuropsychiatry Clin Neurosci. 2018 Fall;30(4):310-317. doi: 10.1176/appi.neuropsych.18030047. Epub 2018 Jul 26.

PMID:
30045680
11.

Differentiating between Alzheimer's Disease and Vascular Cognitive Impairment: Is the "Memory Versus Executive Function" Contrast Still Relevant?

Andriuta D, Roussel M, Barbay M, Despretz-Wannepain S, Godefroy O; Godefroy and GRECogVASC study group.

J Alzheimers Dis. 2018;63(2):625-633. doi: 10.3233/JAD-171097.

PMID:
29689726
12.

Prevalence of Poststroke Neurocognitive Disorders Using National Institute of Neurological Disorders and Stroke-Canadian Stroke Network, VASCOG Criteria (Vascular Behavioral and Cognitive Disorders), and Optimized Criteria of Cognitive Deficit.

Barbay M, Taillia H, Nédélec-Ciceri C, Bompaire F, Bonnin C, Varvat J, Grangette F, Diouf M, Wiener E, Mas JL, Roussel M, Godefroy O; GRECOG-VASC Study Group.

Stroke. 2018 May;49(5):1141-1147. doi: 10.1161/STROKEAHA.117.018889. Epub 2018 Apr 11.

PMID:
29643258
13.

Controlled Education of patients after Stroke (CEOPS)- nurse-led multimodal and long-term interventional program involving a patient's caregiver to optimize secondary prevention of stroke: study protocol for a randomized controlled trial.

Mendyk AM, Duhamel A, Bejot Y, Leys D, Derex L, Dereeper O, Detante O, Garcia PY, Godefroy O, Montoro FM, Neau JP, Richard S, Rosolacci T, Sibon I, Sablot D, Timsit S, Zuber M, Cordonnier C, Bordet R; on the behalf of Strokavenir network.

Trials. 2018 Feb 22;19(1):137. doi: 10.1186/s13063-018-2483-0.

14.

Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.

Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Tréluyer JM, Gelé P, Delmaire C, Blanc F, Mangin JF, Buée L, Touchon J, Hugon J, Vellas B, Galbrun E, Benetos A, Berrut G, Paillaud E, Wallon D, Castelnovo G, Volpe-Gillot L, Paccalin M, Robert PH, Godefroy O, Dantoine T, Camus V, Belmin J, Vandel P, Novella JL, Duron E, Rigaud AS, Schraen-Maschke S, Gabelle A; BALTAZAR study group.

Alzheimers Dement. 2018 Jul;14(7):858-868. doi: 10.1016/j.jalz.2018.01.004. Epub 2018 Feb 17.

15.

Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias.

Mendes A, Bertrand A, Lamari F, Colliot O, Routier A, Godefroy O, Etcharry-Bouyx F, Moreaud O, Pasquier F, Couratier P, Bennys K, Vercelletto M, Martinaud O, Laurent B, Pariente J, Puel M, Epelbaum S, Belliard S, Kaaouana T, Fillon L, Chupin M, Dubois B, Teichmann M; PHRC “CAPP” Study Group.

Neurology. 2018 Mar 20;90(12):e1057-e1065. doi: 10.1212/WNL.0000000000005165. Epub 2018 Feb 14.

PMID:
29444966
16.

Inferior Parietal Cortex Hypoperfusion is the Most Specific Imaging Marker for AD Patients With Positive CSF Biomarker Assays in a Memory Clinic in France.

Andriuta D, Moullart V, Schraen S, Devendeville A, Meyer ME, Godefroy O.

Alzheimer Dis Assoc Disord. 2018 Apr-Jun;32(2):89-93. doi: 10.1097/WAD.0000000000000225.

PMID:
29261520
17.

Mental Simulation of Painful Situations Has an Impact on Posture and Psychophysiological Parameters.

Lelard T, Godefroy O, Ahmaidi S, Krystkowiak P, Mouras H.

Front Psychol. 2017 Nov 21;8:2012. doi: 10.3389/fpsyg.2017.02012. eCollection 2017.

18.

Imaging Characteristics of Venous Parenchymal Abnormalities.

Arnoux A, Triquenot-Bagan A, Andriuta D, Wallon D, Guegan-Massardier E, Leclercq C, Martinaud O, Castier-Amouyel M, Godefroy O, Bugnicourt JM.

Stroke. 2017 Dec;48(12):3258-3265. doi: 10.1161/STROKEAHA.117.017937. Epub 2017 Nov 16.

PMID:
29146874
19.

Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study.

Ceccaldi M, Jonveaux T, Verger A, Krolak-Salmon P, Houzard C, Godefroy O, Shields T, Perrotin A, Gismondi R, Bullich S, Jovalekic A, Raffa N, Pasquier F, Semah F, Dubois B, Habert MO, Wallon D, Chastan M, Payoux P; NEUUS in AD study group, Stephens A, Guedj E.

Alzheimers Dement. 2018 Mar;14(3):293-305. doi: 10.1016/j.jalz.2017.09.009. Epub 2017 Nov 4.

20.

Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort.

Dufouil C, Dubois B, Vellas B, Pasquier F, Blanc F, Hugon J, Hanon O, Dartigues JF, Harston S, Gabelle A, Ceccaldi M, Beauchet O, Krolak-Salmon P, David R, Rouaud O, Godefroy O, Belin C, Rouch I, Auguste N, Wallon D, Benetos A, Pariente J, Paccalin M, Moreaud O, Hommet C, Sellal F, Boutoleau-Bretonniére C, Jalenques I, Gentric A, Vandel P, Azouani C, Fillon L, Fischer C, Savarieau H, Operto G, Bertin H, Chupin M, Bouteloup V, Habert MO, Mangin JF, Chêne G; MEMENTO cohort Study Group.

Alzheimers Res Ther. 2017 Aug 29;9(1):67. doi: 10.1186/s13195-017-0288-0.

21.

Vascular cognitive impairment: Advances and trends.

Barbay M, Taillia H, Nedelec-Ciceri C, Arnoux A, Puy L, Wiener E, Canaple S, Lamy C, Godefroy O, Roussel M; GRECOGVASC Study Group.

Rev Neurol (Paris). 2017 Jul - Aug;173(7-8):473-480. doi: 10.1016/j.neurol.2017.06.009. Epub 2017 Aug 31. Review.

PMID:
28838792
22.

Asleep Robot-Assisted Surgery for the Implantation of Subthalamic Electrodes Provides the Same Clinical Improvement and Therapeutic Window as Awake Surgery.

Lefranc M, Zouitina Y, Tir M, Merle P, Ouendo M, Constans JM, Godefroy O, Peltier J, Krystkowiak P.

World Neurosurg. 2017 Oct;106:602-608. doi: 10.1016/j.wneu.2017.07.047. Epub 2017 Jul 19.

PMID:
28735132
23.

APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.

Lanoiselée HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, Richard AC, Pasquier F, Rollin-Sillaire A, Martinaud O, Quillard-Muraine M, de la Sayette V, Boutoleau-Bretonniere C, Etcharry-Bouyx F, Chauviré V, Sarazin M, le Ber I, Epelbaum S, Jonveaux T, Rouaud O, Ceccaldi M, Félician O, Godefroy O, Formaglio M, Croisile B, Auriacombe S, Chamard L, Vincent JL, Sauvée M, Marelli-Tosi C, Gabelle A, Ozsancak C, Pariente J, Paquet C, Hannequin D, Campion D; collaborators of the CNR-MAJ project.

PLoS Med. 2017 Mar 28;14(3):e1002270. doi: 10.1371/journal.pmed.1002270. eCollection 2017 Mar.

24.

STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease.

Sachdev PS, Lo JW, Crawford JD, Mellon L, Hickey A, Williams D, Bordet R, Mendyk AM, Gelé P, Deplanque D, Bae HJ, Lim JS, Brodtmann A, Werden E, Cumming T, Köhler S, Verhey FR, Dong YH, Tan HH, Chen C, Xin X, Kalaria RN, Allan LM, Akinyemi RO, Ogunniyi A, Klimkowicz-Mrowiec A, Dichgans M, Wollenweber FA, Zietemann V, Hoffmann M, Desmond DW, Linden T, Blomstrand C, Fagerberg B, Skoog I, Godefroy O, Barbay M, Roussel M, Lee BC, Yu KH, Wardlaw J, Makin SJ, Doubal FN, Chappell FM, Srikanth VK, Thrift AG, Donnan GA, Kandiah N, Chander RJ, Lin X, Cordonnier C, Moulin S, Rossi C, Sabayan B, Stott DJ, Jukema JW, Melkas S, Jokinen H, Erkinjuntti T, Mok VC, Wong A, Lam BY, Leys D, Hénon H, Bombois S, Lipnicki DM, Kochan NA; STROKOG.

Alzheimers Dement (Amst). 2016 Nov 18;7:11-23. doi: 10.1016/j.dadm.2016.10.006. eCollection 2017.

25.

Creation of an intensive care unit and organizational changes in an adult emergency department: Impact on acute stroke management.

Puy L, Lamy C, Canaple S, Arnoux A, Laine N, Iacob E, Constans JM, Godefroy O.

Am J Emerg Med. 2017 May;35(5):716-719. doi: 10.1016/j.ajem.2017.01.007. Epub 2017 Jan 10.

PMID:
28096032
26.

Does impaired socioemotional functioning account for behavioral dysexecutive disorders? Evidence from a transnosological study.

Narme P, Roussel M, Mouras H, Krystkowiak P, Godefroy O.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2017 Jan;24(1):80-93. Epub 2016 Apr 7.

PMID:
27054957
27.

Dysexecutive syndrome in Parkinson's disease: the GREFEX study.

Roussel M, Lhommée E, Narme P, Czernecki V, Gall DL, Krystkowiak P, Diouf M, Godefroy O; GREFEX study group.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2017 Sep;24(5):496-507. doi: 10.1080/13825585.2016.1226248. Epub 2016 Sep 1.

PMID:
27585478
28.

Prevalence and profile of cognitive impairment in adult glioma: a sensitivity analysis.

Boone M, Roussel M, Chauffert B, Le Gars D, Godefroy O.

J Neurooncol. 2016 Aug;129(1):123-30. doi: 10.1007/s11060-016-2152-7. Epub 2016 May 30.

PMID:
27241133
29.

What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?

Andriuta D, Moullart V, Schraen S, Devendeville A, Meyer ME, Godefroy O; Alzheimer’s Disease Neuroimaging.

J Alzheimers Dis. 2016;51(3):793-800. doi: 10.3233/JAD-150829.

PMID:
26923012
30.

Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders.

Godefroy O, Bakchine S, Verny M, Delabrousse-Mayoux JP, Roussel M, Pere JJ; REFLEX study group:.

J Alzheimers Dis. 2016;51(3):815-25. doi: 10.3233/JAD-150971.

PMID:
26890770
31.

[Bi-thalamic abnormality].

Puy L, Lamy C, Arnoux A, Zerbib Y, Constans JM, Godefroy O.

Rev Med Interne. 2016 Oct;37(10):714-715. doi: 10.1016/j.revmed.2015.11.006. Epub 2016 Feb 5. French. No abstract available.

PMID:
26857331
32.

The Behavioral and Cognitive Executive Disorders of Stroke: The GREFEX Study.

Roussel M, Martinaud O, Hénon H, Vercelletto M, Bindschadler C, Joseph PA, Robert P, Labauge P, Godefroy O; GREFEX Study Group.

PLoS One. 2016 Jan 29;11(1):e0147602. doi: 10.1371/journal.pone.0147602. eCollection 2016.

33.

Huntington's Disease Revealed by Familial Cervical Dystonia.

Andriuta D, Tir M, Godefroy O, Krystkowiak P.

Mov Disord Clin Pract. 2016 Jan 18;3(4):415-416. doi: 10.1002/mdc3.12311. eCollection 2016 Jul-Aug. No abstract available.

34.

Cross-validation of a Shortened Battery for the Assessment of Dysexecutive Disorders in Alzheimer Disease.

Godefroy O, Martinaud O, Verny M, Mosca C, Lenoir H, Bretault E, Devendeville A, Diouf M, Pere JJ, Bakchine S, Delabrousse-Mayoux JP, Roussel M; GREFEX and REFLEX study groups.

Alzheimer Dis Assoc Disord. 2016 Apr-Jun;30(2):140-4. doi: 10.1097/WAD.0000000000000112.

PMID:
26485496
35.

Executive Functions Deficits After Severe Traumatic Brain Injury: The GREFEX Study.

Azouvi P, Vallat-Azouvi C, Joseph PA, Meulemans T, Bertola C, Le Gall D, Bellmann A, Roussel M, Coyette F, Krier M, Franconie C, Bindschadler C, Diouf M, Godefroy O; GREFEX Study Group (Groupe de Réflexion sur lʼEvaluation des Fonctions Exécutives).

J Head Trauma Rehabil. 2016 May-Jun;31(3):E10-20. doi: 10.1097/HTR.0000000000000169.

PMID:
26394296
36.

Influence of previous physical activity on the outcome of patients treated by thrombolytic therapy for stroke.

Decourcelle A, Moulin S, Sibon I, Murao K, Ronzière T, Godefroy O, Poli M, Cordonnier C, Sagnier S, Lassalle V, Okada Y, Mas JL, Bordet R, Leys D.

J Neurol. 2015 Nov;262(11):2513-9. doi: 10.1007/s00415-015-7875-4. Epub 2015 Aug 15.

PMID:
26275566
37.

Teaching NeuroImages: epilepsia partialis continua revealing PML after allogenic stem cell transplantation.

Andriuta D, Tir M, Perin B, Merle PE, Bryer-Le Breton C, Charbonnier A, Constans JM, Godefroy O.

Neurology. 2015 Aug 4;85(5):e53-4. doi: 10.1212/WNL.0000000000001804. No abstract available.

38.

Do we feel the same empathy for loved and hated peers?

Bucchioni G, Lelard T, Ahmaidi S, Godefroy O, Krystkowiak P, Mouras H.

PLoS One. 2015 May 29;10(5):e0125871. doi: 10.1371/journal.pone.0125871. eCollection 2015.

39.

Freezing behavior as a response to sexual visual stimuli as demonstrated by posturography.

Mouras H, Lelard T, Ahmaidi S, Godefroy O, Krystkowiak P.

PLoS One. 2015 May 20;10(5):e0127097. doi: 10.1371/journal.pone.0127097. eCollection 2015.

40.

The dysexecutive syndrome of Alzheimer's disease: the GREFEX study.

Godefroy O, Martinaud O, Verny M, Mosca C, Lenoir H, Bretault E, Roussel M.

J Alzheimers Dis. 2014;42(4):1203-8. doi: 10.3233/JAD-140585.

PMID:
25024318
41.

Thrombolytic therapy for stroke in patients with preexisting cognitive impairment.

Murao K, Leys D, Jacquin A, Kitazono T, Bordet R, Béjot Y, Kimura K, Godefroy O, Wakisaka Y, Moulin S, Ago T, Sibon I, Bombois S, Mas JL, Hénon H, Pasquier F, Giroud M, Cordonnier C, Okada Y; OPHELIE-COG investigators.

Neurology. 2014 Jun 10;82(23):2048-54. doi: 10.1212/WNL.0000000000000493. Epub 2014 May 14.

PMID:
24827495
42.

Hedonic deficits in Parkinson's disease: is consummatory anhedonia specific?

Loas G, Duru C, Godefroy O, Krystkowiak P.

Front Neurol. 2014 Mar 10;5:24. doi: 10.3389/fneur.2014.00024. eCollection 2014.

43.

Validation of an integrated method for determining cognitive ability: Implications for routine assessments and clinical trials.

Godefroy O, Gibbons L, Diouf M, Nyenhuis D, Roussel M, Black S, Bugnicourt JM; GREFEX study group.

Cortex. 2014 May;54:51-62. doi: 10.1016/j.cortex.2014.01.016. Epub 2014 Feb 7.

44.

Influence of postural threat on postural responses to aversive visual stimuli.

Lelard T, Krystkowiak P, Montalan B, Longin E, Bucchioni G, Ahmaidi S, Godefroy O, Mouras H.

Behav Brain Res. 2014 Jun 1;266:137-45. doi: 10.1016/j.bbr.2014.02.051. Epub 2014 Mar 12.

PMID:
24631393
45.

T2*-weighted findings in prolonged acute migraine aura.

Bugnicourt JM, Canaple S, Lamy C, Deramond H, Godefroy O.

Chin Med J (Engl). 2013 Oct;126(20):4000. No abstract available.

PMID:
24157179
46.

[Dementia: new concepts, new goals].

Pour le comité d’organisation, Hannequin D, Amieva H, Dubois B, Godefroy O, Pasquier F.

Rev Neurol (Paris). 2013 Oct;169(10):677-9. doi: 10.1016/j.neurol.2013.09.002. French. No abstract available.

PMID:
24074818
47.

Loss of emotional responsiveness secondary to left amygdalohippocampectomy performed for the treatment of complex, drug-resistant partial epilepsy.

Hequette J, Narme P, Perin B, Godefroy O, Loas G.

J Neuropsychiatry Clin Neurosci. 2013 Summer;25(3):E55-9. doi: 10.1176/appi.neuropsych.12080195. No abstract available.

PMID:
24026747
48.

Neuropsychological assessment and cerebral vascular disease: the new standards.

Godefroy O; GRECOG-VASC study group, Leclercq C, Bugnicourt JM, Roussel M, Moroni C, Quaglino V, Beaunieux H, Taillia H, Nédélec-Ciceri C, Bonnin C, Thomas-Anterion C, Varvat J, Aboulafia-Brakha T, Assal F.

Rev Neurol (Paris). 2013 Oct;169(10):779-85. doi: 10.1016/j.neurol.2013.07.009. Epub 2013 Aug 30. Review.

PMID:
23999023
49.

Assessment of socioemotional processes facilitates the distinction between frontotemporal lobar degeneration and Alzheimer's disease.

Narme P, Mouras H, Roussel M, Devendeville A, Godefroy O.

J Clin Exp Neuropsychol. 2013;35(7):728-44. doi: 10.1080/13803395.2013.823911. Epub 2013 Aug 12.

PMID:
23930667
50.

Association between caffeine intake and age at onset in Huntington's disease.

Simonin C, Duru C, Salleron J, Hincker P, Charles P, Delval A, Youssov K, Burnouf S, Azulay JP, Verny C, Scherer C, Tranchant C, Goizet C, Debruxelles S, Defebvre L, Sablonnière B, Romon-Rousseaux M, Buée L, Destée A, Godefroy O, Dürr A, Landwehrmeyer B; REGISTRY Study of the European Huntington's Disease Network, Bachoud-Levi AC, Richard F, Blum D, Krystkowiak P; Huntington French Speaking Network.

Neurobiol Dis. 2013 Oct;58:179-82. doi: 10.1016/j.nbd.2013.05.013. Epub 2013 May 31.

PMID:
23732677

Supplemental Content

Loading ...
Support Center